newsfilter
← Latest News
GlobeNewswire·

Avalo Therapeutics to Participate in Upcoming Investor Conferences

  • Avalo Therapeutics (NASDAQ: AVTX) announced its management will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 Fireside Chat on February 11, 2026, at 10:00 am ET.
  • The company's management will attend the Oppenheimer 36th Annual Healthcare Life Sciences Conference Fireside Chat on February 25, 2026, at 10:00 am ET.
  • Live webcasts & replays for both events will be available under the "News / Events" section of the investor relations website at https://ir.avalotx.com for at least 30 days.
  • Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases.
  • The company's lead asset, AVTX-009, is currently in a Phase 2 clinical trial for hidradenitis suppurativa (HS).
  • AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β with high affinity to neutralize its activity.
  • Christopher Sullivan serves as the CFO for media & investor inquiries, while Meru Advisors represents Lauren Glaser as a contact.